Despite it being general knowledge that smoking causes serious health issues, every year tobacco consumption kills more than 9,00,000 people. According to the World Health Organization report, India comes second to China in terms of adult smokers which is equivalent to 106 million.
As one of the biggest generic drug manufacturing countries in the world, India’s pharmaceutical industry has increased by 13% - 14% within the last 5 years. As a result, many companies are looking to take advantage of this growth but are in need of guidance.
Axiostat, the first US Food and Drug Administration (USFDA) approved wound dressing product from India is a user-friendly, compact pack of 8X8 centimeters which ceases unrestrained bleeding from wounds. When applied on a wound, the patch acts on the blood and forms a clot in a minute and turns into a very sticky adhesive patch.
China opens up its pharmaceutical market to its rather hostile neighbor, India while Beijing and Washington have a tiff over President Donald Trump’s renewed warning of added tariffs on Chinese imports worth $200 billion.
After months of inspections, Indian Ministry of Health and Family Welfare have taken a decision to ban the import of Oxytocin in India from 1 July 2018. The government has restricted private manufactures to produce Oxytocin formulations for domestic use, only state-owned Karnataka Antibiotics & Pharmaceuticals Ltd. (KAPL) have been allowed to manufacture and directly supply to registered hospitals and clinics across India.
Last Friday, pharma giant AstraZeneca announced that it had received the go-ahead from the Drug Controller General of India (DCGI) to import and market durvalumab (ImfinziTM) in India. The receipt of this permission paves the way for the launch of durvalumab (ImfinziTM) in India. Durvalumab which is a patented drug of Astra-Zeneca, received permission in India to provide treatment for patients with unresectable non-small cell lung cancer and metastatic urothelial carcinoma.
Key findings of the FHI 2018 allude to the lack of access on account of low skilled physician density and a low number of hospital beds. The study also highlighted the fact that semi-urban and rural areas are yet to leverage the advancements of digital healthcare. It also stated that healthcare professionals in the country were open to the deployment of futuristic technology such as AI and virtual reality in healthcare as compared to the general population.
On Sunday, the World Health Organization praise India's progress in reducing the maternal mortality ratio (MMR) by 77%. According to their statistics rates have dropped from 556 per 1,00,000 live births in 1990 to 130 per 1,00,000 live births in 2016. As a result of achieving this milestone, hopes are high for India to be on track towards reaching their Sustainable Development Goal (SDG) target of an MMR below 70 by 2030.
Niti Aayog is focusing on proposals to encourage domestic manufacturing of medical devices following orders from the Prime Minister's Office, said the expert. The meeting was focused on identifying the problems in local manufacturing and quality of the devices produced in India and also to spot the solution for the issues.
Determined to cap the profits of private hospitals in Delhi and the NCR region, Delhi health minister Satyendra Jain has announced an array of new rules. He clearly stated that hospitals will be mandated to sell essential medicines at MRP and can no longer charge a markup.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.